Skip to main content
. 2022 Dec 1;8:e2200205. doi: 10.1200/GO.22.00205

FIG 1.

FIG 1

(A) OS and (B) PFS curves of the patients treated with atezolizumab plus bevacizumab. OS, overall survival; PFS, progression-free survival.